<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03358693</url>
  </required_header>
  <id_info>
    <org_study_id>A100/12</org_study_id>
    <nct_id>NCT03358693</nct_id>
  </id_info>
  <brief_title>Anti-cytokine Signatures in Inflammatory Skin Disease</brief_title>
  <official_title>Systematic Profiling of Anti-cytokine Signatures in the Treatment of Chronic Inflammatory Skin Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Stephan Weidinger</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot project intends to examine the utility of a systems medicine approach to identify
      regulatory networks and their perturbation in psoriasis and atopic dermatitis, and to obtain
      a comprehensive perspective on disease and disease control by integrating and modelling data
      across multiple cellular levels and time following specific blockade of single
      pathophysiological factors through use of licensed biologics during routine care as systems
      biology challenge. To this end, ultra-deep phenotyping and prospective molecular
      characterization in short time-intervals and different disease equilibrium states will be
      carried out in targeted small sets of patients. The different layers and types of clinical
      and molecular information will then be integrated (integrative personal omics profiling iPOP)
      for generating insights into disease pathways and for extraction of molecular signatures that
      correspond to clinical severity scores. It will provide a good starting point for planning
      future trials aimed at identifying biological patterns useful for guiding targeted treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of molecular signatures associated with treatment</measure>
    <time_frame>Baseline and day 1, day 7, day 14, day 42, day 84</time_frame>
    <description>Changes of transcriptome and microbiome signatures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of molecular signatures associated with treatment response</measure>
    <time_frame>Baseline and day 1, day 7, day 14, day 42, day 84</time_frame>
    <description>Changes of transcriptome and microbiome signatures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of molecular signatures associated with disease severity/remission</measure>
    <time_frame>Baseline and day 1, day 7, day 14, day 42, day 84</time_frame>
    <description>Changes of transcriptome and microbiome signatures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Eczema area and severity index (EASI) score</measure>
    <time_frame>Baseline and day 1, day 7, day 14, day 42, day 84</time_frame>
    <description>Clinical severity score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Score of Atopic Dermatitis (SCORAD)</measure>
    <time_frame>Baseline and day 1, day 7, day 14, day 42, day 84</time_frame>
    <description>Clinical severity score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Psoriasis Area Severity Index (PASI) score</measure>
    <time_frame>Baseline and day 1, day 7, day 14, day 42, day 84</time_frame>
    <description>Clinical severity score</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Atopic Dermatitis</condition>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Psoriasis patients receiving ustekinumab</arm_group_label>
    <description>Ustekinumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psoriasis patients receiving infliximab</arm_group_label>
    <description>Infliximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psoriasis patients receiving secukinumab</arm_group_label>
    <description>Secukinumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atopic dermatitis patients receiving dupilumab</arm_group_label>
    <description>Dupilumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab</intervention_name>
    <description>Subject receives Ustekinumab open-label as per guidelines</description>
    <arm_group_label>Psoriasis patients receiving ustekinumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>Subject receives Infliximab open-label as per guidelines</description>
    <arm_group_label>Psoriasis patients receiving infliximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>Subject receives Secukinumab open-label as per guidelines</description>
    <arm_group_label>Psoriasis patients receiving secukinumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab</intervention_name>
    <description>Subject receives Dupilumab open-label as per guidelines</description>
    <arm_group_label>Atopic dermatitis patients receiving dupilumab</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, skin biopsies, swabs, tape strips, stool
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with moderate to severe psoriasis or atopic dermatitis who receive specified
        biologics from their treating dermatologist during routine care
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent and comply with the protocol

          -  At least 18 years of age.

          -  Diagnosis of chronic psoriasis or atopic dermatitis for at least 3 years prior to
             enrollment.

          -  PASI score ≥ 10 or EASI score ≥ 16

          -  Investigator Global Assessment (IGA) ≥ 3

          -  Subject receives systemic therapy within routine care (in-label use of biologics)

        Exclusion Criteria:

          -  Subject is unable to provide written informed consent or comply with the protocol.

          -  Subject is younger than 18 years of age.

          -  Subject has had psoriasis or atopic dermatitis for less than 3 years prior to
             enrollment.

          -  Subject with mild psoriasis or atopic dermatitis (PASI&lt;16 or EASI&lt;16 and IGA&lt;3) or is
             not a candidate or is not eligible for systemic treatment

          -  Having used immunosuppressive/immunomodulating therapy or phototherapy within 4 weeks
             before the baseline visit.

          -  Treatment of selected skin areas to be examined with topical corticosteroid or topical
             calcineurin inhibitor within 1 week before the baseline visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Stephan Weidinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, university Hospital Schleswig-Holstein, Campus Kiel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephan Weidinger, MD</last_name>
    <email>sweidinger@dermatology.uni-kiel.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sascha Gerdes, MD</last_name>
    <email>sgerdes@dermatology.uni-kiel.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Weidinger, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Sascha Gerdes, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2017</study_first_submitted>
  <study_first_submitted_qc>November 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2017</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Schleswig-Holstein</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Stephan Weidinger</investigator_full_name>
    <investigator_title>Head, Inflammatory Skin Disease Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Ustekinumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

